Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization

Figure 1

Progression-free (PFS) and overall survival (OS) curves of AFP responder and non-responder. PFS was similar between AFP responders and non-responders (8.0 vs. 5.5 months; log rank test, P = 0.150; (A)) whereas OS were significantly better in AFP responder than non-responder. (34.9 vs. 13.2 months; log rank test, P = 0.020; (B)).

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us